Topical Neck Cooling Without Systemic Hypothermia Attenuates Myocardial Ischemic Injury and Post-ischemic Reperfusion Injury

Aimee Zhang, Radhika Rastogi, Katherine M. Marsh, Boris Yang, Di Wu, Irving L. Kron and Zequan Yang*

Department of Surgery, University of Virginia Health System, Charlottesville, VA, United States

Background: Following acute myocardial infarction (MI), irreversible damage to the myocardium can only be reduced by shortening the duration between symptom onset and revascularization. While systemic hypothermia has shown promising results in slowing pre-revascularization myocardial damage, it is resource intensive and not conducive to prehospital initiation. We hypothesized that topical neck cooling (NC), an easily implemented therapy for en route transfer to definitive therapy, could similarly attenuate myocardial ischemia-reperfusion injury (IRI).

Methods: Using an in vivo mouse model of myocardial IRI, moderate systemic hypothermia or NC was applied following left coronary artery (LCA) occlusion and subsequent reperfusion, at early, late, and post-reperfusion intervals. Vagotomy was performed after late NC in an additional group. Hearts were harvested to measure infarct size.

Results: Both hypothermia treatments equally attenuated myocardial infarct size by 60% compared to control. The infarct-sparing effect of NC was temperature-dependent and timing-dependent. Vagotomy at the gastroesophageal junction abolished the infarct-sparing effect of late NC. Cardiac perfusate isolated following ischemia had significantly reduced cardiac troponin T, HMGB1, cell-free DNA, and interferon α and β levels after NC.

Conclusions: Topical neck cooling attenuates myocardial IRI in a vagus nerve-dependent manner, with an effect comparable to that of systemic hypothermia. NC attenuated infarct size when applied during ischemia, with earlier initiation resulting in superior infarct sparing. This novel therapy exerts a cardioprotective effect without requiring significant change in core temperature and may be a promising practical strategy to attenuate myocardial damage while patients await definitive revascularization.

Keywords: therapeutic hypothermia, myocardial infarction, topical hypothermia, ischemia-reperfusion injury, vagal activation
INTRODUCTION

Ischemic heart disease remains the single leading cause of death in the United States, with acute myocardial infarction (MI) accounting for the considerable morbidity and mortality from this condition (1). Final infarct size, which is the main predictor of outcomes following MI, is directly related to the duration of time from symptom onset to definitive treatment restoring coronary flow and myocardial tissue perfusion (2–5). Thus, the key to maximal salvage is summarized by the phrase "Time is Muscle"—shortening patients’ symptom-to-door and door-to-balloon time in order to minimize the final volume of infarcted myocardium (4, 6, 7). Strategies to reduce the final infarct size include implementation of mild to moderate systemic hypothermia, which has been shown to protect against MI and slow the rate of infarction, allowing for increased ischemic time prior to reperfusion without increasing infarct size (8, 9). Multiple clinical trials have since evaluated the effect of endovascular cooling during primary percutaneous coronary intervention (PCI). It has been shown that patients who are systemically cooled to <35°C early during MI have a significant reduction in infarct size at the time of reperfusion (10). However, the induction of systemic hypothermia is resource intensive and must be performed with supervision by medical professionals, making the challenge of initiating these therapies rapidly after initial symptom onset likely unsurmountable (7).

We recently identified an alternative therapeutic hypothermia approach, topical neck cooling (NC), which could potentially exert similar infarct-sparing effects to systemic hypothermia via stimulation of the vagus nerve by temperature reduction. The link between the vagus nerve and cardioprotection has been reported by our lab (11) and others (12–16), and the vagus nerve has been demonstrated to be directly activated by temperature changes (17). In the current study, we investigated the cardioprotective effect of topical neck cooling, hypothesizing that locally decreased temperatures in the soft tissue and encompassed structures of the neck, without inducing systemic hypothermia, would attenuate myocardial ischemic and reperfusion injury (IRI). Furthermore, we evaluated the role of the timing of NC application and the depth of NC in achieving a protective effect against myocardial IRI. This topical approach to hypothermic therapy, which is non-invasive and easily implemented after MI, may prolong the therapeutic window to reach definitive reperfusion interventions and thereby could lead to improved patient outcomes.

METHODS

This study complied with the Guide for the Care and Use of Laboratory Animals as recommended by the U.S. National Institutes of Health ensuring that all animals received humane care. The University of Virginia Animal Care and Use Committee reviewed and approved the study protocol.

Animals and Experimental Protocols

C57BL/6 wild type mice (male and female aged 9–12 weeks, purchased from The Jackson Laboratory, Bar Harbor, ME) were used in the study. Mice underwent 40 min of left coronary artery (LCA) occlusion followed by 60 min of reperfusion before infarct size was evaluated by TTC-Phthalo blue staining. Topical neck cooling experimental groups underwent early cooling starting 5 min after LCA occlusion to 5 min after reperfusion, late cooling from 30 min after LCA occlusion to 30 min after reperfusion, late cooling after vagotomy at gastroesophageal junction (GEJ) performed 5 min prior to LCA occlusion, or cooling from 5 min after reperfusion to 45 min after reperfusion. Methods to achieve moderate systemic hypothermia and topical neck cooling. NC, topical neck cooling; GEJ, gastro-esophageal junction; LCA, left coronary artery; min.

Abbreviations: CAP, cholinergic anti-inflammatory pathway; cDNA, cell-free DNA; CP, cardiac perfusate; cTnT, cardiac troponin T; DAMP, Damage-associated molecular pattern; GEJ, Gastro-esophageal junction; HMGB1, High mobility group box protein 1; IFNa, Interferon alpha; IFNB, Interferon beta; IRI, Ischemia-reperfusion injury; IS, Myocardial infarct size; LCA, Left coronary artery; LV, Left Ventricle; MI, Myocardial infarction; NC, Topical neck cooling; PCI, Percutaneous coronary intervention; PBS, phosphate buffered saline; TTC, 2,3,5-Triphenyltetrazolium chloride.
Surgical Procedures to Induce Myocardial Infarction in Intact Mice

The details of the surgical procedure with a video are published in JTCVS (18). Briefly, mice were anesthetized with intraperitoneal Avertin (Tribromoethanol) at 250 mg/kg, placed in supine position, and orally intubated with a PE-60 tube. Respiration was maintained with a rodent ventilator with room air, at a frequency of 130 strokes/min and a tidal volume of 8–10 µl/g weight. The left pleural cavity was entered by cutting the intercostal muscles and left 3rd and 4th ribs with a cautery pen and scissors to expose the heart. An 8-0 Prolene suture was passed beneath the LCA 1 mm inferior to the left atrium and tied over a short piece of PE-60 tubing to occlude the LCA for 40 min. Significant ECG changes, including widening of the QRS and elevation of the ST segment complex (monitored with a PowerLab data recording unit, ADInstruments), and color changes in the risk region were used to confirm successful LCA occlusion. Reperfusion was achieved by untying the ligature and removing the PE-60 tubing. Anesthesia was maintained with additional Avertin doses of 125 mg/kg given every 30 min. Core body temperature was monitored throughout the experiment with a rectal thermocouple interfaced to a digital thermometer (Omega Co).

Determination of Myocardial Infarct Size

After 40 min of ischemia with or without 60 min of reperfusion, mice were euthanized under deep anesthesia and the heart was excised, cannulated through the ascending aorta with a blunt 23-gauge needle, and perfused with 3 ml 37°C 1% triphenyltetrazolium chloride (TTC) in phosphate buffered saline (PBS, pH = 7.4). The LCA was then re-occluded by retying the suture left around LCA. The heart was then perfused with 0.3–0.5 ml 2% Phthalo Blue (Heubach Ltd, Fairless Hills, PA) to delineate the non-ischemic tissue. The left ventricle was cut into 5–7 transverse slices and fixed in 10% neutral buffered formalin solution. Each slice was weighed and photographed. The sizes of calculated as a percentage of the corresponding slice multiplied by weight of the slice (18–21).

Vagotomy at the Gastroesophageal Junction

After induction of general anesthesia and intubation, a vertical midline epigastric incision was sharply made. The stomach was retracted caudally to expose the GEJ. The anterior and posterior vagal nerve trunks were isolated and divided. The laparotomy was closed in layers using 5-0 Nylon.

Systemic Hypothermia and Topical Neck Cooling

Systemic hypothermia was achieved by encircling the mice with ice-filled 3/4-inch rubber tubing to achieve a core rectal temperature of 30–32°C. NC was achieved by wrapping the ventral neck with ice-filled 3/4-inch rubber tubing (Figure 1B). To achieve a milder depth of localized cooling, an additional group underwent mild NC with application of rubber tubing filled with 20°C water. The cooling appliances were exchanged at frequent intervals to maintain a consistent temperature until the full treatment period was completed. In all NC groups, rectal temperature was maintained between 36.0 and 37.0°C using a heating lamp.

Analysis of Cardiac Perfusate

Following 40 min of LCA occlusion only, the hearts were harvested, cannulated through the ascending aorta with a blunt 23-gauge needle, and perfused with 500 µl of 37°C PBS (pH = 7.4) cycled three times. The CP was collected and centrifuged at 3,000 rpm for 20 min and then recollected after cellular sediments were discarded. Levels of cell-free DNA (cfDNA) were evaluated using Nanodrop; levels of high mobility group box 1 (HMGB1), cardiac troponin T (cTnT), and interferon alpha (IFNα) and beta (IFNβ) were evaluated using Western Blot (2, 18). Antibodies to HMGB1, cTnT, IFNα, and IFNβ were purchased from Abcam and ThermoFisher respectively.

Statistical Analysis

Comparisons between groups were performed with one-way analysis of variance with Bonferroni’s correction for multiple comparisons and unpaired Student’s t-test. Paired Student’s t-test was used to analyze changes in heart rate. Prism 7 (GraphPad Software Inc., La Jolla, CA) was used to perform statistical calculations. Data are presented as mean±standard error of the mean, with a p-value of 0.05 indicating statistical significance. Drs. Katherine Marsh and Zequan Yang had full access to all data in the study and take responsibility for its integrity and data analysis.

RESULTS

Systemic Hypothermia and Topical Neck Cooling Equally Attenuate Myocardial Ischemia/Reperfusion Injury (IRI)

C57BL6 male mice underwent 40 min of LCA occlusion and 60 min of reperfusion (40′/60′ IRI). Five minutes after LCA occlusion, mice underwent either systemic hypothermia to achieve a core body temperature of 30–32°C or NC to achieve a neck subcutaneous tissue temperature of 14–17°C for 40 min. Risk regions (ischemic area as a percentage of left ventricle, LV, mass) were comparable among the control and hypothermic groups (p = NS, Figure 2A). Myocardial infarct size (IS, as a percentage of the risk region area) was 53 ± 3% in normothermic control mice. Systemic hypothermia during ischemia reduced IS to 19 ± 4% (p < 0.05 vs. control). NC reduced IS to 24 ± 5% (p < 0.05 vs. control, p = NS vs. systemic hypothermia, Figure 2A). In female C57BL6 mice undergo 40′/60′ IRI, risk regions were also comparable (36 ± 2% NC vs. 39 ± 2% control, p = NS) between the normothermic control and NC groups, and NC similarly attenuated IS (15 ± 5% NC vs. 49 ± 2%, p < 0.05, Figure 2B).
The Infarct-Sparing Effect of Neck Cooling Is Temperature-Dependent and Requires Early Application During Ischemia

C57BL/6 male mice underwent 40′/60′ IRI. NC was achieved with either room-temperature (20°C) water-filled 3/4-inch rubber tubing to achieve mild NC or ice-filled 3/4-inch rubber tubing applied 5 min after LCA occlusion for a 40-min duration. In two additional groups, NC was initiated later, starting 10 min prior to reperfusion, with ice-filled tubing with or without vagotomy at the level of GEJ. Temperatures were measured 10 min after NC interventions in all groups in the neck subcutaneous tissue, in the left pleural space, and rectally. In the normothermic control, mild NC, early NC, and late NC groups, neck subcutaneous temperatures were 37.3, 31.9, 16.9, and 15.4°C respectively, left
pleural cavity temperatures were 37.1, 35.8, 32.3, and 32.7°C, and rectal temperatures were 36.8, 36.5, 36.2, and 36.6°C (Figure 3A). Mild NC mice had significantly lower neck and left pleural temperatures than normothermic controls ($p < 0.05$, Figure 3A), but IS was comparable between these groups ($p = \text{NS}$, Figures 3B, 4). Both NC (early and late) groups had significantly lower neck and left pleural temperatures and smaller IS than the mild NC and normothermic control groups ($p < 0.05$, Figures 3A,B, 4). However, the late NC group had a significantly larger IS than the group with early initiation of NC. The infarct-sparing effect of NC was eliminated by vagotomy at the GEJ (Figure 3B). The infarct-sparing effect of NC also disappeared when application was initiated after the onset of reperfusion (NC for 40 min starting 5 min after reperfusion, IS 53 ± 3%, $p = \text{NS}$ vs. control).

Neck Cooling Attenuates Ischemic Myocardial Injury

Mice underwent 40 min of LCA occlusion without reperfusion (40'/0' IRI) to evaluate ischemia-induced injury. NC was applied 5 min after LCA occlusion for 35 min. After 40 min of ischemia, hearts were harvested to collect CP and perform TTC-Phthalo Blue staining to calculate IS. IS in normothermic mice was 30 ± 3% compared to 15 ± 3% in NC mice ($p < 0.05$, Figure 5). The 40'/0' IS was 60% of the IS after 40'/60' IRI with or without corresponding neck cooling ($p < 0.05$, Figures 2A, 4). NC also significantly reduced cTrnI, HMGB1, cfDNA, IFNα, and IFNβ in CP ($p < 0.05$ vs. control, Figure 6). Next, CP from control mice with 40'/0' IRI was administered to naïve mice without IRI at a treatment dose of 2 µl/g i.v. bolus. An additional group of naïve mice was treated with PBS at the same volume with a 2 µl/g i.v. bolus. In normothermic mice 15 min after treatment, 40'/0' CP decreased plasma acetylcholine levels and increased splenic tissue acetylcholine levels compared to PBS administration ($p < 0.05$, Figure 7). NC attenuated this decrease in plasma acetylcholine following CP administration ($p < 0.05$ vs. PBS & vs. CP control) and abolished the change in splenic tissue acetylcholine levels ($p = \text{NS}$ vs. PBS, $p < 0.05$ vs. CP control).

Neck Cooling Without Systemic Hypothermia Slows Heart Rate

Baseline heart rate measured in naïve anesthetized mice ($n = 4$) was 511 ± 15 beats per minute (bpm). After 10 min of NC treatment, the mean heart rate decreased to 416 ± 10 bpm, an 18% reduction from baseline ($p < 0.05$). This significant heart rate reduction was sustained throughout the remainder of the neck cooling period (30 min) and persisted after removal of the cooling appliance. This effect was observed without any corresponding significant change in core body temperature (Figure 8).
FIGURE 6 | NC decreased cardiac troponin T, HMGB1, cell-free DNA, and type I interferon (IFNα and IFNβ) levels in cardiac perfusate after ischemia. Cardiac perfusate was collected after 40 min of left coronary artery occlusion without reperfusion from normothermic mice or mice that underwent NC. Levels of cfDNA were measured by Nanodrop; levels of cTnT, HMGB1, and IFNα and IFNβ were measured by Western Blot. NC, topical neck cooling; cTnT, cardiac troponin T; cfDNA, cell-free DNA; * p < 0.05 vs. control.

DISCUSSION

Using a mouse model of myocardial IRI, we found that NC produced an infarct-sparing effect comparable to that seen with moderate systemic hypothermia. We distinguished that the cardioprotective effect of NC is timing- and dose-dependent; this therapy optimally should be applied early after initial symptom onset and prior to reperfusion. Furthermore, we identified that NC exerted a cardioprotective effect against both ischemic injury and post-ischemic reperfusion injury. The mechanism of this intervention involves activation of the vagal acetylcholine anti-inflammatory pathway to increase the myocardium’s resistance to ischemia and reduce inflammatory responses during post-ischemic reperfusion.

Following the onset of an MI, the key to salvaging ischemic myocardium is shortening the time between coronary artery occlusion and reperfusion of the ischemic myocardium (2–5). Early recognition of MI and timely transportation to the hospital remain the only opportunities to shorten ischemic duration (4, 22), but faster transportation to interventional centers is improbable in the current healthcare landscape, and thus far, clinical treatments to protect myocardium during the ischemic period are lacking (7, 23). At this time, most potential therapies target early reperfusion as an adjunct to definitive revascularization (23). During the ischemic period, coronary occlusion precludes delivery of medication to the at-risk myocardium, rendering pharmaceutical interventions ineffectual during the ischemia phase of acute MI. Moreover,
several promising preclinical drug therapies have not shown consistent benefit in clinical trials (7, 24). Pre-conditioning, by either ischemic or pharmacologic methods, prior to MI may increase myocardial tolerance to ischemic insult and attenuate ischemic injury (23, 25–28). However, its clinical application in acute MI is not feasible and often can only be delivered in the peri-revascularization period. Furthermore, randomized controlled trials of remote ischemic preconditioning under controlled elective situations have failed to show consistent clinically relevant beneficial effects (27, 29). When used during the MI itself, smaller clinical trials have suggested benefit with remote ischemic conditioning but a large phase III trial showed no difference in heart failure and death after a year (30–32).

Mild to moderate systemic hypothermia has been demonstrated to be protective against acute MI and allows for prolonged time to reperfusion without a concomitant increase in infarct size (8–10, 31). This therapeutic approach also allows for its cardioprotective effect to be implemented during both the ischemic and reperfusion phases of acute MI. However, induction of systemic hypothermia is resource intensive and cannot be performed without the presence of medical personnel and thus has been difficult to translate clinically (7, 31). Thus, this practice has not been implemented as part of pre-hospital management of acute coronary syndrome, and a large gap in patient care persists.

To circumvent the logistical difficulties of inducing systemic hypothermia, we developed a therapeutic hypothermia approach of topical neck cooling and demonstrated that it attenuates myocardial IRI to a similar degree to systemic hypothermia (Figure 2). It has been reported that mild (35°C) and, to an even more significant degree, moderate (32°C) systemic hypothermia result in an infarct-sparing effect (33). Multiple clinical trials have since evaluated the effect of endovascular cooling during primary PCI, and it has been shown that patients with anterior STEMI who were cooled to <35°C early during MI have a significant reduction in infarct size at the time of reperfusion (10). Using an in vivo mouse model undergoing 40 min of LCA occlusion and 60 min of reperfusion, we found that moderate systemic hypothermia attenuates myocardial infarct size by 60% in comparison to normothermic mice. By cooling the neck to 15°C while maintaining normal core temperature, we found that simple topical neck cooling produced a similar infarct-sparing effect to that seen with moderate systemic hypothermia (Figure 2A). The infarct-sparing effect of NC is dose-dependent and effective only when it is applied before reperfusion (Figure 3). Given that the neck subcutaneous tissue temperature is similar between mild NC, which did not result in an infarct-sparing effect, and systemic hypothermia (data not shown), the cardioprotective mechanisms underlying NC may differ from that of systemic hypothermia.

Therapeutic hypothermia produces multifactorial beneficial effects resulting in an overall protective anti-inflammatory state, inhibition of apoptosis, and activation of cell survival pathways (34, 35). One of the mechanisms underlying hypothermic cardiac protection is vagal activation to modulate the IRI-associated inflammatory response (17, 36), possibly via a postsynaptic process (36). Preclinical and small clinical studies have demonstrated electrical vagal nerve stimulation itself has been clinically effective in reducing infarct size (14–16, 31). Moreover, neck cooling (via the application of a neck wrap containing frozen ice packs) (37) and electrical stimulation of the vagus nerve at the neck have been shown to relieve migraine headaches (38), raising the possibility that activation of the vagus nerve could be a shared mechanism underlying the beneficial effects of neck cooling. In support of this, a recent clinical trial demonstrated that topical neck cooling at the lateral neck stimulates the vagus nerve and produces a parasympathetic nervous system response in healthy participants (39). In the current study, the infarct-sparing effect of NC was abolished by vagotomy at the GEJ (Figures 3B, C), further suggesting that the cardioprotective effect of NC against IRI is mediated by vagus nerve stimulation in the neck region. There was also evidence of parasympathetic activation by NC, with a significant decrease in heart rate observed during NC (Figure 8). In addition to being a major component of the parasympathetic nervous system, the vagus nerve has several other cardioprotective
mechanisms (40), and has a recognized anti-inflammatory role with its efferent fibers mediating the cholinergic anti-inflammatory pathway (CAP) (41). The CAP is mediated through the binding of acetylcholine released from distal vagus nerve terminals to \(\alpha\)-7-nicotinic cholinergic receptors (\(\alpha7nAChR\)) to ultimately inhibit the release of pro-inflammatory cytokines, such as TNF\(\alpha\), by peripheral macrophages (42) and from the spleen (Figure 7) (43). In this study, NC significantly decreased splenic tissue acetylcholine levels while concomitantly increasing plasma acetylcholine (Figure 7), indicating that NC does modulate acetylcholine release, with the ultimate result of increased splenic clearance of this neurotransmitter, likely after its binding to downstream targets, and entry into peripheral circulation. Our previous studies have demonstrated that the spleen plays a central role in amplifying inflammatory responses and mediating myocardial IRI (2, 18), and that therapies to modulate the spleen to an anti-inflammatory phenotype attenuate myocardial IRI (11). Moreover, a cardioprotective role of the vago-splenic axis has been implicated in a preclinical study demonstrating infarct reduction via remote ischemic preconditioning in myocardial IRI, further establishing the role of both the spleen and vagus nerve in mediating the progression of infarction (13, 44). Taken together, these results suggest that the cardioprotective effect of NC may be attributable to activation of the vagal nerve, possibly via the CAP, to modulate splenic-derived inflammatory responses involved in post-ischemic myocardial reperfusion injury.

The extent of ischemic myocardial injury, defined by the duration from symptom onset to definitive treatment, determines post-ischemic reperfusion injury and therefore also final infarct size, which is the major predictor of clinical outcomes (2−5). Systemic therapeutic hypothermia attenuates ischemic myocardial injury and allows for longer ischemic time prior to reperfusion without consequent increase in infarct size (8−10). In this study we found that NC protects the heart not only from post-ischemic reperfusion injury but also from initial ischemic injury alone. During 40 min of LCA occlusion without reperfusion, NC attenuated ischemic myocardial infarct size by 50% compared to normothermic control as defined by TTC-blue staining (Figure 5) and significantly decreased CP levels of cTnT, cfDNA and HMGB1 (Figure 6). We have previously demonstrated that these two important DAMPs are released from ischemic myocardium during reperfusion and activate inflammatory pathways to induce reperfusion injury; both cfDNA and HMGB1 are vital to induce myocardial IRI (2, 18). The diminished release of cfDNA and HMGB1 from ischemic myocardium following NC mitigates the de novo inflammatory response within ischemic myocardium, as additionally reflected by the reduced CP levels of pro-inflammatory cytokines IFN\(\beta\) and IFN\(\beta\) (Figure 6), and consequently is conducive to a reduced post-ischemic reperfusion injury as we have reported previously (18). Plasma dendritic cells are a potential target activated by cfDNA to produce IFN\(\beta\) and IFN\(\beta\) and effect an injurious pro-inflammatory response (45−47). We plan to further evaluate the role of this innate immune cell subset in mediating myocardial IRI in future experiments.

Another mechanism through which NC-induced vagal activation may prove cardioprotective is through resulting bradycardia, given that NC demonstrated a significant decrease in HR. Bradycardia has long been thought to reduce cardiomyocyte oxygen consumption, and heart rate reduction therapies, including ivabradine or beta blockers such as metoprolol, given during the ischemic period of MI have been investigated with potential, but often equivocal, benefit (48−52). Such drugs may have significant benefit through alternate mechanisms independent of their induced bradycardia, such as with ivabradine (52). Within our study, late application of NC demonstrated decreased infarct size, albeit with less effect than when applied early, implicates a larger impact on the modulation of reperfusion injury. While our study underscores the impact of NC through inflammatory modulation, the effect of bradycardia cannot be excluded. The extent through which bradycardia plays an additional role warrants further investigation for neck cooling.

A limitation of this study is that the possibility of direct cooling of the heart contributing to NC’s observed protective effect against ischemic injury and reperfusion injury cannot be excluded. We did find that NC resulted in moderate hypothermia in the pleural cavity (Figures 3A, 4B). Theoretically, NC may have directly lowered myocardial temperature either through local transfer from the neck subcutaneous tissues or return of cooled venous blood to the heart, and resultant reduced metabolic demands on the myocardium could, in part, account for the cardioprotective effect against ischemic and/or...
reperfusion injury. Studies with either large animals or more targeted cooling devices may help to differentiate these effects. Additionally, the role of the vagal cholinergic anti-inflammatory pathway in facilitating the cardioprotective effect of NC against ischemic myocardial injury and post-ischemic reperfusion injury remains to be defined.

In conclusion, NC without lowering core body temperature attenuated myocardial IRI to a similar degree to moderate systemic hypothermia. We demonstrated that NC reduces both ischemic and post-ischemic reperfusion injury via activation of the vagal cholinergic anti-inflammatory pathway. Clinically, NC may prolong the treatment window to achieve reperfusion without enlarging subsequent infarct size and would avoid the myriad negative side effects associated with systemic hypothermia. NC is a novel treatment that is straightforward to implement, readily accessible, and could be easily applied in the pre-hospital setting by non-medical personnel immediately after onset of acute MI to improve patient outcomes.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by University of Virginia Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

AZ and ZY contributed to conception and design of the study. AZ, BY, DW, and ZY participated in acquisition of data via experiments. KM and ZY performed the statistical analysis. IK and ZY participated in funding acquisition. AZ wrote the first draft of the manuscript. AZ, KM, ZY, and RR wrote sections of the manuscript and performed critical revisions. ZY supervised all aspects of the study. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

This work was supported in part by NIH R01HL130082, Commonwealth Health Research Board (CHRB) Grant Award #207-12-21, and University of Virginia George A. Beller, M.D. Research Award T32HL007849 (ZY) and T32HL007849-21A1 (IK).
REFERENCES

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the american heart association. Circulation. (2020) 141:e139–596. doi: 10.1161/CIR.0000000000000875

2. Tian Y, Pan D, Chordia MD, French BA, Kron IL, Yang Z. The spleen contributes importantly to myocardial infarction exacerbation during post-ischemic reperfusion in mice via signaling between cardiac hmbg1 and splenic rage. Basic Res Cardiol. (2016) 111:62. doi: 10.1007/s00422-016-0583-0

3. Yang Z, Linden J, Berr SS, Kron IL, Beller GA, French BA. Timing of adenosine 2a receptor stimulation relative to reperfusion has differential effects on infarct size and cardiac function as assessed in mice by MRI. J Am Physiol Heart Circ Physiol. (2008) 295:H2139–46. doi: 10.1152/jappl.00091.2008

4. Antman EM. Time Is muscle: translation into practice. J Am Coll Cardiol. (2008) 52:1216–21. doi: 10.1016/j.jacc.2008.07.011

5. Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese WM, et al. Degree C) therapeutic hypothermia in porcine acute myocardial infarction. Am J Physiol Heart Circ Physiol. (2017) 313:H844–53. doi: 10.1152/ajpheart.00493.2016

6. Horneffer PJ, Healy B, Gott VL, Gardner TJ. The rapid evolution of a paradigm for providing percutaneous coronary intervention to remote st segment elevation myocardial infarction patients. Ther Hypothermia Temp Manag. (2020). doi: 10.1089/ther.2019.0039

7. Dae MW, Gao DW, Sessler DI, Chair K, Stillson CA. Effect of endovascular cooling on myocardial temperature, infarct size, and cardiac output in human-sized pigs. Am J Physiol Heart Circ Physiol. (2002) 282:H1584–91. doi: 10.1152/ajpheart.00090.2001

8. Cheung E, Al-Khalidi HR, Baddour LM, Kishore PS, Gislason GH, et al. Extending time to reperfusion with mild therapeutic hypothermia: a report from the American Heart Association. J Cardiovasc Med. (2018) 12:361–7. doi: 10.1093/jtcvs/215.1.196

9. Tian Y, French BA, Kron IL, Yang Z. Splenic leukocytes mediate the hyperglycemic exacerbation of myocardial infarct size in mice. Basic Res Cardiol. (2015) 110:39. doi: 10.1007/s00422-015-0496-3

10. Tian Y, Miao B, Charles EJ, Wu D, Kron IL, French BA, et al. Stimulation of the beta2 adrenergic receptor at reperfusion limits myocardial reperfusion injury via an interleukin-10-dependent anti-inflammatory pathway in the spleen. Circ J. (2018) 82:8289–36. doi: 10.1253/circj.18-0061

11. Charles EJ, Tian Y, Zhang A, Wu D, Mehaffey JH, Gigliotti JC, et al. Myocardial infarct-sparing effect of adenosine A2a receptor activation is due to its action on CD4+ T lymphocytes. Circulation. (2006) 114:2056–64. doi: 10.1161/CIRCULATIONAHA.106.649244

12. Imori Y, Akasaka T, Shishido K, Ochiai T, Tobiita K, Yamanaka F, et al. Prehospital transfer pathway and mortality in patients undergoing primary percutaneous coronary intervention. Circ J. (2015) 79:2000–8. doi: 10.1253/circj.CJ-14-0678

13. Lieder HR, Kleinbongard P, Skyschally A, Hagelschuer H, Chilian WM, Heusch G, Bersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J. (2017) 38:777–84. doi: 10.1093/eurheartj/ehw224

14. Babcock E, Westerheide KD, Lefer DJ, Vessal T, Eger EI, et al. Low-Amplitude, left vagus nerve stimulation for the treatment of ischemia and reperfusion injury in patients undergoing orthopaedic surgery: a randomized controlled trial. Br J Anaesth. (2018) 120:198–200. doi: 10.1016/j.bja.2017.09.005

15. Meybohm P, Bein B, Brosteau O, Cramer I, Gruenewald M, Stoppe C, et al. A multicenter trial of remote ischemic preconditioning for open heart surgery. Asian Cardiovasc Thorac Ann. (2014) 22:276–83. doi: 10.1177/0218492313481223

16. Wojcik B, Knapp M, Gorski J. Non-ischemic heart preconditioning. J Pharm Pharmacol. (2016) 68:197–32. doi: 10.1111/jphp.12014

17. Park SK, Hur M, Yoo S, Choi JY, Kim WH, Kim JT, et al. Effect of remote ischaemic preconditioning in patients with ischaemic heart disease undergoing orthopaedic surgery: a randomized controlled trial. Br J Anaesth. (2018) 120:198–200. doi: 10.1016/j.bja.2017.09.005

18. Bhatnagar S, Saitoastomoro S, Suyatna FD, Soejoeno G. Ischemic preconditioning reduces apoptosis in open heart surgery. Asian Cardiovasc Thorac Ann. (2014) 22:276–83. doi: 10.1177/0218492313481223

19. Meybohm P, Bein B, Brosteau O, Cramer I, Gruenewald M, Stoppe C, et al. A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med. (2015) 373:1397–407. doi: 10.1056/NEJMoa1413579

20. Gaspar A, Lourenço AP, Pereira MÁ, Azevedo P, Roncon-Albuquerque R, Marques J, et al. Randomized controlled trial of remote ischemic conditioning in st elevation myocardial infarction as adjuvant to primary angioplasty (Ric-Stemi), Basic Res Cardiol. (2018) 113:14. doi: 10.1007/s00395-018-0672-3

21. Heusch G. Myocardial ischaemia–reperfusion injury and cardioprotection in perspective. Nature Reviews Cardiology. (2020) 17:773–89. doi: 10.1038/s41569-020-0403-y

22. Hausenloy DJ, Kharbanda RK, Muller UK, Ramalll M, Aaroee J, Butler R, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (Condil-2/Eric-Ppci): a single-blind randomised controlled trial. Lancet. (2019) 394:1415–24. doi: 10.1016/S0140-6736(19)32039-2

23. Dash R, Mitsutake Y, Pyun WB, Dawoud F, Tachibana A, et al. Dose-dependent cardioprotection of moderate (32 Degrees C) versus mild (35 Degrees C) therapeutic hypothermia in porcine acute myocardial infarction. JACC Cardiovasc Interv. (2018) 11:195–205. doi: 10.1016/j.jcin.2017.08.056

24. Kurisu K, Yenari MA. Therapeutic hypothermia for ischemic stroke: pathophysiology and future promise. Neuropharmacology. (2018) 134:92–9. doi: 10.1016/j.neuropharm.2017.08.025

25. Willis GR, J, Charles EL, Givens CA, Chordia MD, Davies SW, Yang Z, et al. Effect of hypothermia on splenic leukocyte modulation and survival duration in severely septic rats. J Surg Res. (2017) 215:196–203. doi: 10.1016/j.jss.2017.03.060
36. Pickoff AS, Stolfi A, Campbell P. Temperature dependency of the vagal chronotropic response in the young puppy: an ‘environmental-autonomic interaction’. J Auton Nerv Syst. (1997) 64:107–14. doi: 10.1016/S0165-1838(97)00024-6

37. Sprouse-Blum AS, Gabriel AK, Brown JP, Yee MH. Randomized controlled trial: targeted neck cooling in the treatment of the migraine patient. Hawaii J Med Public Health. (2013) 72:237–41.

38. Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized presto study. Neurology. (2018) 91:e364–e73. doi: 10.1212/WNL.0000000000005857

39. Jungmann M, Vencatachellum S, Van Ryckeghem D, Vogele C. Effects of cold stimulation on cardiac-vagal activation in healthy participants: randomized controlled trial. JMIR Form Res. (2018) 2:e10257. doi: 10.2196/10257

40. Heusch G. Vagal cardioprotection in reperfused acute myocardial infarction. JACC: Cardiovascular Interventions. (2017) 10:1521–2. doi: 10.1016/j.jcin.2017.05.063

41. Bonaz B, Sinniger V, Pellissier S. Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. J Physiol. (2016) 594:5781–90. doi: 10.1113/JPH271539

42. Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med. (2003) 9:125–34. doi: 10.1007/BF03402177

43. Olofsson PS, Katz DA, Rosas-Ballina M, Levine YA, Valdés-Ferrer SI, et al. A7 Nicotinic acetylcholine receptor (A7nachr) expression in bone marrow-derived non-T cells is required for the inflammatory reflex. Mol Med. (2012) 18:539–43. doi: 10.2119/molmed.2011.00405

44. Heusch G. The spleen in myocardial infarction. Circ Res. (2019) 124:26–8. doi: 10.1161/CIRCRESAHA.118.314331

45. Ali S, Mann-Nuttel R, Schulze A, Richter L, Alferink J, Scheu S. Sources of type 1 interferons in infectious immunity: plasmacytoid dendritic cells not always in the driver’s seat. Front Immunol. (2019) 10:778. doi: 10.3389/fimmu.2019.00778

46. Lai L, Zhang A, Yang B, Charles EJ, Kron IL, Yang Z. Plasmacytoid dendritic cells mediate myocardial ischemia/reperfusion injury by secreting type 1 interferons. J Am Heart Assoc. (2021) 10:e020754. doi: 10.1161/JAHA.121.020754

47. Swiecki M, Colonna M. Type 1 interferons: diversity of sources, production pathways and effects on immune responses. Curr Opin Virol. (2011) 1:463–75. doi: 10.1016/j.coviro.2011.10.026

48. García-Ruiz JM, Fernández-Jiménez R, García-Alvarez A, Pizarro G, Galán-Arriola C, Fernández-Friera I, et al. Impact of the timing of metoprolol administration during stemi on infarct size and ventricular function. J Am Coll Cardiol. (2016) 67:2093–104. doi: 10.1016/j.jacc.2016.02.050

49. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Matoes A, et al. Early intravenous beta-blockers in patients with St-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol. (2016) 67:2705–15. doi: 10.1016/j.jacc.2016.03.522

50. Giannakopoulos G, Noble S. Should we be using upstream beta-blocker therapy for acute myocardial infarction? Curr Cardiol Rep. (2021) 23:66. doi: 10.1007/s11886-021-01494-3

51. Hoedemaker NP, Roolvink V, de Winter RJ, van Royen N, Fuster V, García-Ruiz JM, et al. Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction: a patient-pooled meta-analysis of randomized clinical trials. Eur Heart J Acute Cardiovasc Care. (2020) 9:469–77. doi: 10.1177/2048872619830609

52. Kleinbongard P, Gedik N, Witting P, Freedman B, Klöcker N, Heusch G. Pleiotropic, heart rate-independent cardioprotection by Ivabradine. Br J Pharmacol. (2015) 172:4380–90. doi: 10.1111/bph.13220

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Rastogi, Marsh, Yang, Wu, Kron and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.